Results 191 to 200 of about 337,841 (333)

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera   +14 more
wiley   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang   +7 more
wiley   +1 more source

Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Objective To determine the optimal anticoagulation intensity of warfarin in a South‐East Asian population with moderate‐to‐severe rheumatic mitral stenosis. Methods A multicentre, retrospective study examined patients with rheumatic mitral stenosis who had not undergone valve replacement or repair and required long‐term warfarin therapy at two ...
Punyawee Puchsaka   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy